Roxane Laboratories, Inc. v. Camber Pharmaceuticals Inc., No. 16-1028 (Fed. Cir. Nov. 17, 2016)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Roxane Laboratories, Inc. (“Roxane”) appeals from a stipulated judgment of noninfringement following the decision of the United States District Court for the Di s- trict of New Jersey construing the claims of U.S. Patent 8,563,032 (“the ’032 patent”). See Roxane Labs., Inc. v. Camber Pharm. Inc. , No. 14 -4042, 2015 WL 4393785 (D.N.J. July 15, 2015) (claim construction order); Roxane Labs., Inc. v. Camber Pharm. Inc. , No. 14 -4042, ECF No. 247 (D.N.J. S ept. 9, 2015) (final judgment) .